Bio-Techne. has filed a patent for methods to detect target proteins and nucleic acids in samples using secondary antibodies attached to oligonucleotides. The process involves signal-generating complexes and hybridization detection. GlobalData’s report on Bio-Techne gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Bio-Techne Corp - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Bio-Techne, Peptide pharmacophores was a key innovation area identified from patents. Bio-Techne's grant share as of January 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

Method for detecting target protein in biological sample

Source: United States Patent and Trademark Office (USPTO). Credit: Bio-Techne Corp

A patent application (Publication Number: US20240035073A1) describes a method for detecting a target protein in a fixed biological sample. The method involves contacting the sample with a secondary antibody or fragment attached to an oligonucleotide, followed by a signal-generating complex that hybridizes to the oligonucleotide, resulting in the detection of a signal. The secondary antibody can be specific for antigens on primary antibodies targeting the protein, with variations including multiple secondary antibodies for different or the same antigens.

Furthermore, the patent application details the use of various secondary antibodies, such as monoclonal, bispecific, or chimeric antibodies, attached to oligonucleotides via linkers like HyNic or SMCC. The method also includes the use of blocking agents and crosslinking agents in sample preparation. The signal-generating complex may contain amplifiers and detectable labels like fluorescent or chromogenic moieties. The application also covers kits for detecting target proteins, including secondary antibodies attached to oligonucleotides and signal-generating complexes, with the option of including control or reference samples for validation purposes.

To know more about GlobalData’s detailed insights on Bio-Techne, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies